Bronchiolitis
Introduction
Bronchiolitis is a common acute respiratory tract infection that primarily affects the small airways, known as bronchioles, in the lungs of infants and young children, typically those under two years of age. [1] It stands as a leading cause of hospitalization for infants globally. [2]
Biological Basis
The overwhelming majority of bronchiolitis cases are caused by viral infections. Respiratory Syncytial Virus (RSV) is the most frequent pathogen, responsible for a significant proportion of infections. [3] Other viruses, including rhinovirus, parainfluenza virus, influenza virus, and adenovirus, can also lead to the condition. Upon viral infection, the epithelial cells lining the bronchioles become inflamed, leading to swelling, increased mucus production, and necrosis. These pathological changes result in the narrowing and obstruction of the small airways, impeding airflow and causing characteristic respiratory distress. [4] While viral infection is the direct trigger, an individual's genetic background may influence susceptibility to infection, the severity of the disease course, and the potential for long-term respiratory complications.
Clinical Relevance
The initial symptoms of bronchiolitis often mimic a common cold, presenting with rhinorrhea (runny nose), cough, and a low-grade fever. As the infection progresses, symptoms typically escalate to signs of respiratory distress, such as tachypnea (rapid breathing), wheezing, intercostal and subcostal retractions, and nasal flaring. Diagnosis is primarily clinical, relying on the characteristic symptoms and findings from a physical examination. [4] Management is largely supportive, focusing on maintaining adequate hydration, ensuring sufficient oxygenation, and providing respiratory support as needed. Severe cases frequently necessitate hospitalization for supplemental oxygen therapy, intravenous fluids, and close medical monitoring. Potential complications include dehydration and respiratory failure. Furthermore, some research suggests a correlation between severe bronchiolitis in infancy and an elevated risk of developing recurrent wheezing or asthma later in childhood. [4]
Social Importance
Bronchiolitis carries significant social and public health importance due to its high incidence, particularly during seasonal outbreaks, and the considerable burden it places on healthcare systems, especially pediatric emergency departments and intensive care units. It is a major contributor to infant morbidity and, in vulnerable populations or settings with limited resources, mortality. [2] Public health strategies emphasize preventive measures, such as rigorous hand hygiene and avoiding exposure to sick individuals, to limit viral transmission. For select high-risk infants, including those born prematurely or with certain underlying health conditions, immunoprophylaxis with palivizumab is available to reduce the severity of RSV-related bronchiolitis. [1] Ongoing scientific efforts are dedicated to the development of effective vaccines and antiviral therapies to further mitigate the global impact of this widespread childhood illness.
Limitations in Data Sourcing and Phenotype Ascertainment
The research relies exclusively on electronic medical record (EMR) data collected from a single medical center, which may limit the generalizability of findings to broader populations or different healthcare systems. This approach also presents challenges with unrecorded comorbidities, potentially leading to false-negative outcomes in both case and control groups. While the low prevalence of many diseases in the study population might mitigate these false-negative rates, the absence of comprehensive comorbidity data could still influence the precision of disease associations.
Furthermore, diagnostic recording practices within the healthcare system can influence the reliability of phenotype ascertainment, as many diagnoses depend on physician decisions to order specific tests, potentially resulting in the documentation of unconfirmed diagnoses. To address this, a criterion of at least three diagnoses was implemented for case selection, aiming to reduce false-positive results. However, the hospital-centric nature of the database also means an absence of "subhealthy" individuals, as most participants have at least one documented condition, potentially biasing control group selection and affecting the observed disease prevalence and genetic associations.
Ancestry-Specific Genetic Architecture and Generalizability
The study's focus on the Taiwanese Han population means that the identified genetic architectures and disease associations are specific to this ancestry. Direct application of these findings, particularly Polygenic Risk Score (PRS) models, to populations of different ancestries may be limited. For instance, a variant like rs6546932 in the SELENOI gene demonstrated a notable discrepancy in effect size between the Taiwanese Han population (OR of 1.58) and the UK Biobank (OR of 1.21), underscoring the impact of population-specific genetic backgrounds on disease associations. This highlights the critical need to tailor PRS models and interpret genetic findings with careful consideration of the specific ancestral context to avoid exacerbating health disparities.
Statistical Considerations and Model Efficacy
The efficacy of Polygenic Risk Score (PRS) models in this study was found to correlate primarily with the cohort size rather than the number of variants included in the model. This suggests that for diseases or phenotypes with smaller participant cohorts, the predictive power of their respective PRS models may be inherently limited. Consequently, the robustness and clinical utility of these models could vary significantly across the diverse range of diseases analyzed, depending on the available sample sizes for each specific condition.
Variants
The C19orf67 gene, located on chromosome 19, encodes a protein whose precise function is still being actively investigated, but it is generally understood to play a role in cellular processes, potentially related to immune response or inflammation. Genetic variations within this gene, such as rs140690816, can influence its expression or the activity of the protein it produces, thereby affecting relevant biological pathways. Understanding these genetic underpinnings is crucial for deciphering individual susceptibility to diseases and variable responses to environmental factors, a key focus in population-level genetic studies. [5] Such studies often rely on comprehensive genomic data, including millions of variants, to identify disease-associated genetic markers. [5]
The single nucleotide polymorphism (SNP) rs140690816 is a specific point mutation within the C19orf67 gene. While its direct functional impact on bronchiolitis is a subject of ongoing research, variants in genes involved in immune regulation and inflammatory pathways are often implicated in respiratory conditions. Bronchiolitis, an acute viral infection of the lower respiratory tract, particularly affects infants and young children, leading to inflammation and obstruction of the small airways. Genetic predispositions can modulate the severity of the disease, the likelihood of hospitalization, or the risk of developing recurrent wheezing and asthma later in life. [5] Genome-wide association studies (GWAS) are instrumental in identifying such genetic associations, analyzing vast datasets to pinpoint variants linked to specific health outcomes. [5]
The relevance of rs140690816 to bronchiolitis could stem from its potential to alter the host's immune response to common respiratory viruses like Respiratory Syncytial Virus (RSV), a primary cause of bronchiolitis. For instance, if this variant affects the efficiency of viral clearance or the magnitude of inflammatory cytokine production, it could influence disease susceptibility or severity. Further research is needed to elucidate the exact molecular mechanisms by which C19orf67 and its variants contribute to the pathophysiology of bronchiolitis and other overlapping respiratory traits, such as asthma and recurrent wheezing. The study of population-specific genetic architectures is vital, as genetic effects can vary significantly across different ancestral groups. [5]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs140690816 | C19orf67 | bronchiolitis |
Large-Scale Cohort Investigations and Longitudinal Patterns
The HiGenome cohort, a significant biobank initiative, serves as a robust foundation for extensive population studies within the Taiwanese Han population, encompassing 323,397 participants. [5] This substantial cohort integrates nearly two decades of electronic medical record (EMR) data, collected longitudinally from 2003 to 2021, with recruitment still ongoing. [5] The prolonged follow-up period is a critical asset for observing disease progression and temporal patterns, with a notable proportion of participants benefiting from follow-up durations exceeding 15 years. [5] This allows for in-depth analysis of long-term health outcomes and the evolution of disease associations over time within this specific East Asian demographic. [5]
The sheer volume of diagnostic instances within this cohort underscores its utility for population-level research, escalating from approximately 800,000 in 2003 to nearly 7 million by 2021. [5] This continuous expansion in clinical data enriches the capacity for comprehensive analyses of disease patterns and the influence of various factors on health outcomes over a substantial period. [5] The cohort's strategic design, drawing participants from highly populated towns and districts across Taiwan through a major academic medical center and its affiliates, enhances its representativeness for the country's diverse regions. [5]
Epidemiological Approaches and Demographic Correlates
Epidemiological investigations within large-scale cohorts like HiGenome leverage extensive EMR data, systematically categorized into 1085 distinct PheCodes, to identify broad disease associations and patterns. [5] These studies provide insights into general demographic characteristics of the participant population, which includes individuals ranging from 0 to 111 years of age, with an overall male-to-female ratio of 45.3:54.7. [5] Analysis across numerous traits within the cohort consistently indicates that the incidence of most diseases tends to increase with age, as evidenced by disease groups generally exhibiting a higher median age compared to control groups. [5] Furthermore, gender-specific patterns are observed across various traits, reflecting the overall cohort distribution while also highlighting specific disparities linked to disease characteristics. [5]
The methodological approach involves case-control stratification, where cases are meticulously defined by three or more diagnostic instances conforming to specific PheCode criteria, while controls comprise individuals without the PheCode-defined disease. [5] This rigorous framework facilitates the study of prevalence patterns and enables the adjustment of key demographic factors such as age and sex in statistical regression models. [5] The increasing annual volume of diagnostic instances within the EMRs, from 2003 to 2021, provides an expanding dataset for tracking and understanding disease burdens within the Taiwanese Han population over time. [5]
Cross-Population Genetic Architecture and Ancestry Considerations
Cross-population comparisons are fundamental for deciphering the varied genetic architecture of diseases, underscoring the critical need for ancestry-specific studies. [5] Research conducted within the Taiwanese Han population has revealed notable differences in genetic associations when contrasted with populations such as those in the UK Biobank. [5] For example, a specific variant, rs6546932 in the SELENOI gene, demonstrated a distinct odds ratio of 1.58 in the Taiwanese Han population, significantly differing from an effect size corresponding to an odds ratio of 1.21 observed in the UKBB. [5] These findings highlight the presence of population-specific genetic effects and emphasize the imperative of developing and validating polygenic risk score (PRS) models tailored to specific ancestries to ensure their predictive accuracy and clinical utility. [5]
Further insights into ancestry-specific genetic variations include the observation of a higher prevalence of certain HLA subtypes, such as HLA-A11:01 and HLA-B40:01, in Southern Han Chinese individuals compared to Han Chinese individuals from Beijing. [5] Such geographic and ethnic group differences in genetic predispositions are crucial for fostering a more comprehensive understanding of disease susceptibility across diverse populations. [5] By concentrating on the Taiwanese Han population, the HiGenome cohort provides invaluable data for exploring these unique genetic landscapes and their implications for disease risk within East Asian populations, contributing to a broader global genetic context. [5]
Methodological Frameworks and Generalizability
The study design implemented within the HiGenome cohort employs a robust framework for genetic association studies, integrating comprehensive genotypic data derived from custom SNP arrays and whole-genome sequencing with extensive electronic medical records. [5] Phenotypes are meticulously classified using PheCodes, which are systematically mapped from International Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification (ICD-9-CM and ICD-10-CM) diagnostic codes, ensuring standardized and consistent disease definitions. [5] Rigorous quality control measures are applied to the genetic data, including stringent filtering criteria for call rates, missingness, Hardy-Weinberg equilibrium, and minor allele frequencies, alongside the careful exclusion of related individuals to prevent inflationary effects. [5] These stringent methodologies are paramount for maintaining the integrity, reliability, and validity of the genome-wide association studies (GWAS) and phenome-wide association studies (PheWAS) conducted. [5]
The substantial sample size of over 320,000 participants significantly enhances the statistical power to detect meaningful genetic associations and to construct effective polygenic risk score (PRS) models. [5] However, the research acknowledges a key consideration for generalizability: the predictive power of PRS models is closely linked to cohort size, and the importance of considering ancestry-specific genetic architectures for accurate risk prediction. [5] Statistical analyses primarily utilize logistic regression models to determine associations, which are carefully adjusted for potential confounding factors such as age, sex, and principal components of ancestry. [5] While the data collection is centered at a single institution and its affiliated branches, the broad recruitment from highly populated regions across Taiwan enhances the representativeness of the cohort within the broader Taiwanese Han population. [5]
Frequently Asked Questions About Bronchiolitis
These questions address the most important and specific aspects of bronchiolitis based on current genetic research.
1. Why do some babies get bronchiolitis easily, but others don't?
Your baby's genetic makeup can play a big role in how susceptible they are to viral infections like bronchiolitis. Variations in genes that affect immune response and inflammation, such as those related to the C19orf67 gene, can influence how easily a virus takes hold. This means some babies are naturally more prone to catching it than others, even with similar exposures.
2. My baby got really sick; why was it so severe for them?
The severity of bronchiolitis can be influenced by your baby's individual genetic background. While viruses are the direct cause, certain genetic variations can lead to a stronger inflammatory response or less effective viral clearance in the bronchioles. This can result in more swelling, mucus, and airway obstruction, making the disease course much more severe for some infants.
3. Will my child's severe bronchiolitis cause asthma later?
There is research suggesting a correlation between severe bronchiolitis in infancy and an elevated risk of developing recurrent wheezing or asthma later in childhood. This connection might be partly due to shared genetic predispositions that affect how your child's airways react to infection and inflammation. So, while not a direct cause, it can be a significant risk factor.
4. If I had it bad as a baby, will my child too?
Your family's genetic history can influence your child's risk. While not a certainty, if you had a severe case, your child might inherit some of the genetic predispositions that made you more susceptible or prone to severe symptoms. These genetic factors can affect how their immune system responds to the virus.
5. Why do some families seem to get bronchiolitis more often?
Beyond environmental exposure, shared genetic factors within a family can contribute to a higher incidence of bronchiolitis. Family members can share genetic variations that influence immune function or airway reactivity, making children in those families more susceptible to infection or to developing symptoms when exposed to common respiratory viruses.
6. Does my family's background affect my baby's risk?
Yes, your ancestral background can influence your baby's genetic risk for bronchiolitis. Genetic architectures and disease associations can vary significantly across different populations. Specific genetic variants might have different effects or prevalence in various ethnic groups, meaning a genetic risk factor in one ancestry might not translate directly to another.
7. Can my baby still get it even if I'm super careful?
Unfortunately, yes. While good hygiene and avoiding sick contacts are crucial, your baby's genetic predisposition also plays a role. Even with careful prevention, if your baby has genetic variations that make them highly susceptible to the common viruses that cause bronchiolitis, they can still contract it. Genetics influence how their body reacts to exposure.
8. What would a genetic test tell me about my baby's risk?
A genetic test could potentially identify specific genetic variations in your baby that are associated with increased susceptibility to bronchiolitis or a more severe disease course. For instance, it might highlight variants in genes involved in immune response or inflammation, like C19orf67. This information helps understand individual risk, though it's not a definitive prediction.
9. Why does my child keep getting chest infections after bronchiolitis?
A severe episode of bronchiolitis in infancy can sometimes be linked to ongoing respiratory issues. Some children may have an underlying genetic predisposition that makes their airways more sensitive or prone to inflammation even after the initial infection clears. This can lead to recurrent wheezing or increased susceptibility to subsequent respiratory infections.
10. Why do some babies recover faster from bronchiolitis?
Individual genetic differences can influence how quickly a baby's immune system clears the viral infection and how effectively their body repairs the damaged airway tissues. Variations in genes affecting immune response and cellular repair mechanisms mean that some babies are genetically better equipped to recover more rapidly than others, even from similar infections.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] American Academy of Pediatrics. "Bronchiolitis: Clinical Practice Guideline for the Diagnosis, Management, and Prevention of Bronchiolitis." Pediatrics, vol. 134, no. 5, 2014, pp. e1474-e1502.
[2] World Health Organization. "Respiratory Syncytial Virus (RSV)." WHO, 17 Aug. 2023, www.who.int/news-room/fact-sheets/detail/respiratory-syncytial-virus-(rsv).
[3] Centers for Disease Control and Prevention. "RSV (Respiratory Syncytial Virus)." CDC, 22 Nov. 2023, www.cdc.gov/rsv/index.html.
[4] Kliegman, Robert M., et al. Nelson Textbook of Pediatrics. 21st ed., Elsevier, 2020.
[5] Liu, T. Y., et al. "Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population." Science Advances, vol. 11, eadt0539, 4 June 2025.